Arcellx, Inc. (ACLX) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 226 transactions totaling $282.2M, demonstrating a bearish sentiment with -$99.7M in net insider flow. The most recent transaction on Feb 25, 2026 involved a sale of 11,219 shares valued at $1.3M.
No significant insider buying has been recorded for ACLX in the recent period.
No significant insider selling has been recorded for ACLX in the recent period.
Based on recent SEC filings, insider sentiment for ACLX is bearish with an Insider Alignment Score of 32/100 and a net flow of -$99.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Arcellx, Inc. (ACLX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading ACLX stock, having executed 226 transactions in the past 90 days. The most active insider is Jill Carroll (Executive), who has made 10 transactions totaling $128.3M.
Get notified when executives and directors at ACLX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | Gilson Michelle | CHIEF FINANCIAL OFFICER | Sale | 11,219 | $113.82 | $1.3M | C-SuiteLarge |
| Jan 14, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | Sale | 5,882 | $68.51 | $403.0K | |
| Jan 13, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | Sale | 7,437 | $65.51 | $487.2K | |
| Jan 12, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | Sale | 6,131 | $64.15 | $393.3K | |
| Jan 6, 2026 | Gilson Michelle | CHIEF FINANCIAL OFFICER | Option Exercise | 20,530 | $N/A | $0 | C-Suite |
| Jan 6, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | Option Exercise | 13,064 | $N/A | $0 | |
| Jan 3, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | Option Exercise | 16,520 | $N/A | $0 | |
| Jan 2, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | Option Exercise | 13,021 | $N/A | $0 | |
| Nov 17, 2025 | Heery Christopher | Executive | Sale | 340 | $90.00 | $30.6K | |
| Oct 15, 2025 | Gilson Michelle | Executive | Sale | 5,364 | $91.04 | $488.3K | |
| Oct 6, 2025 | Gilson Michelle | Executive | Sale | 1,064 | $86.22 | $91.7K | |
| Oct 3, 2025 | Gilson Michelle | Executive | Sale | 4,882 | $86.00 | $419.9K | |
| Sep 30, 2025 | Heery Christopher | Executive | Sale | 5,300 | $80.55 | $426.9K | |
| Sep 30, 2025 | Heery Christopher | Executive | Sale | 14,204 | $81.46 | $1.2M | Large |
| Sep 30, 2025 | Heery Christopher | Executive | Sale | 1,530 | $82.20 | $125.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 116 | $190.9M | 58.9% |
Purchase(P) | 7 | $91.3M | 28.1% |
Payment(F) | 1 | $38.4M | 11.8% |
Exercise(M) | 54 | $3.8M | 1.2% |
Other(J) | 37 | $0 | 0.0% |
Conversion(C) | 11 | $0 | 0.0% |
Insider selling pressure at Arcellx, Inc. has increased, with 19 insiders executing 226 transactions across all time. Total sales of $190.9M significantly outpace purchases of $91.3M, resulting in a net outflow of $99.7M. However, 56% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.